Business
Chimeric IPO: What ASX stockspert Bhavdip143 likes so much about the $35m CAR T play – Stockhead
Institutional investors have queued up to buy stock in Chimeric’s IPO ‘CAR T cell therapy is one of the hottest areas in biotech’ ASX stocks commentator Bhavdip143…
Link copied toclipboard
- Institutional investors have queued up to buy stock in Chimeric’s IPO
- ‘CAR T cell therapy is one of the hottest areas in biotech’ ASX stocks commentator Bhavdip143
- IPO for $35m will fully fund stage one and two clinical trials for CAR T cell treatment
CAR T cell treatment company Chimeric Therapeutics (ASX:CHM) is understood to have easily achieved its IPO fundraising target of $35m ahead of its ASX listing timed for Monday.
Institutional investors have expressed strong interest…
Continue Reading
-
Business18 hours agoThe pros and cons of buying CBA shares in September
-
Noosa News18 hours agoRent changes on way for hundreds of social housing recipients following government review
-
Business14 hours agoWhere will Berkshire Hathaway be in 1 year?
-
Noosa News17 hours agoPolice reject claims about detained protester; SEQ train lines to be disrupted; BlueCare to cut enrolled nurses